James Francis Hulvat

Title: James Francis Hulvat: Innovator in Pharmaceutical Formulations

Introduction

James Francis Hulvat is a notable inventor based in Bend, Oregon. He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors for various diseases. His work is characterized by a focus on innovative formulations that can lead to improved therapeutic outcomes.

Latest Patents

Hulvat holds a patent for a Bruton's tyrosine kinase (Btk) inhibitor. The patent describes the compound 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, along with novel pharmaceutical formulations. This invention includes pharmaceutical compositions that utilize the Btk inhibitor, which can be used alone or in combination with other therapeutic agents. The applications of this inhibitor are aimed at treating autoimmune diseases, heteroimmune diseases, cancer, including lymphoma, and various inflammatory conditions.

Career Highlights

Hulvat is currently associated with Pharmacyclics, Inc., where he continues to advance his research and development efforts. His work has been instrumental in the creation of innovative treatments that address complex medical challenges.

Collaborations

Some of his notable coworkers include Cassandra Shu and Harisha Atluri, who contribute to the collaborative environment that fosters innovation at Pharmacyclics, Inc.

Conclusion

James Francis Hulvat's contributions to pharmaceutical formulations, particularly in the area of Bruton's tyrosine kinase inhibitors, highlight his role as a key innovator in the field. His work not only advances scientific knowledge but also has the potential to improve patient outcomes in various diseases.